Vericel Corp

Our common stock is currently trading on the NASDAQ Stock Market under the symbol “VCEL”.

Holders of Record

As of January 31, 2025 there were approximately 166 holders of record of our common stock.

Dividends

We have never paid cash dividends on our common stock and we do not anticipate paying such cash dividends in the foreseeable future. We currently anticipate that we will retain all future earnings, if any, for use in the development of our business.

Stock Performance Graph

The performance graph set forth below shall not be deemed “soliciting material” or to be “filed” with the SEC. This graph will not be deemed “incorporated by reference” into any filing under the Securities Act or the Exchange Act, whether such filing occurs before or after the date hereof, except to the extent that the Company explicitly incorporates it by reference into in such filing.

Set forth below is a line graph comparing the cumulative total shareholder return on Vericel’s common stock with the cumulative total return of (i) the NASDAQ Composite Index, and (ii) the NASDAQ Biotechnology Index, for the period from December 31, 2019 through December 31, 2024. The comparison assumes that a hypothetical $100 was invested on December 31, 2019 in our common stock and in both of the foregoing indices. All values assume reinvestment of the pre-tax value of dividends paid by companies included in these indices. The historical stock price performance of our common stock shown in the graph below is not necessarily indicative of future stock price performance, and we do not make or endorse any predictions as to future stockholder returns.

Table of Contents

Purchases of Equity Securities by the Issuer

There were no repurchases of shares of common stock made during the year ended December 31, 2024.

Rule 10b5-1 Trading Plans

During the three months ended December 31, 2024, the following Section 16 officers and directors adopted, modified orterminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act):

•On November 14, 2024, Heidi Hagen, amember of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 24,000 shares of our common stock between March 3, 2025, and March 27, 2026.

•On November 15, 2024, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement. Mr. Mara subsequently amended that trading arrangement on November 26, 2024. The amended trading arrangement provides for the potential sale of up to 88,500 shares of our common stock between March 3, 2025, and December 31, 2025.

•On November 19, 2024, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 30,000 shares of our common stock between March 3, 2025, and February 27, 2026.

•On December 2, 2024, Dominick Colangelo, Vericel Corporation’s President and Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 131,008 shares of our common stock between March 12, 2025, and June 2, 2025.

Additionally, there were no “non-Rule 10b5-1 trading arrangements” (as defined in Item 408 of Regulation S-K of the Exchange Act)adopted, modified orterminated during the three months ended December 31, 2024 by our Section 16 officers or directors.